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Abstract 
Background: Pathologic vascular smooth muscle cell (VSMC) proliferation and migration after vascular injury pro‑
motes the development of occlusive vascular disease. Therefore, an effective chemical agent to suppress aberrant 
proliferation and migration of VSMCs can be a potential therapeutic modality for occlusive vascular disease such as 
atherosclerosis and restenosis. To find an anti‑proliferative chemical agent for VSMCs, we screened an in‑house small 
molecule library, and the selected small molecule was further validated for its anti‑proliferative effect on VSMCs using 
multiple approaches, such as cell proliferation assays, wound healing assays, transwell migration assays, and ex vivo 
aortic ring assay.
Results: Among 43 initially screened small molecule inhibitors of kinases that have no known anti‑proliferative 
effect on VSMCs, a spleen tyrosine kinase (Syk) inhibitor (BAY61‑3606) showed significant anti‑proliferative effect on 
VSMCs. Further experiments indicated that BAY61 attenuated the VSMC proliferation in both concentration‑ and time‑
dependent manner, and it also significantly suppressed the migration of VSMCs as assessed by both wound healing 
assays and transwell assays. Additionally, BAY61 suppressed the sprouting of VSMCs from endothelium‑removed 
aortic rings.
Conclusion: The present study identified a Syk kinase inhibitor as a potent VSMC proliferation and migration inhibi‑
tor and warrants further studies to elucidate its underlying molecular mechanisms, such as its primary target, and to 
validate its in vivo efficacy as a therapeutic agent for restenosis and atherosclerosis.
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Background
Normal vascular smooth muscle cells (VSMCs) main-
tain a minimal proliferation rate and active contractility 
[1]. However, non-physiologic stimuli, such as excessive 
cytokines, shear stress, vascular injury, or inflammation, 
can promote the phenotypic switch of VSMCs from a 
contractile type to a synthetic phenotype [2, 3], leading 
to the development of occlusive vascular diseases [4, 5]. 
Such aberrant proliferation and migration of VSMCs 
limit the long-term efficacy of the clinical interventions 
such as angioplasty, stents, and coronary bypass [6]. To 
overcome this problem of excessive VSMC prolifera-
tion, advanced approaches (i.e., drug-eluting stents) have 
been tried and produced some promising results [7]. 
Nevertheless, the incidence of drug-eluding stent failure 
still remains at approximately 10%, [7, 8]. Furthermore, 
although different modalities, including calcium chan-
nel blockers, antiplatelet drugs, and angiotensin con-
verting enzyme inhibitors, have been tried to control 
occlusive vascular disease, the results were not consistent 
[9]. Therefore, searching alternative means to control the 
aberrant proliferation and migration of VSMCs is still an 
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important task for developing an optimized therapeutics 
to treat occlusive disease.
In the present study, we screened number of small mol-
ecule inhibitors of six major kinase subfamilies, to find an 
alternative therapeutic agent for suppressing VSMC pro-
liferation and migration based on the results of multiple 
experiments, such as cell proliferation assays, wound heal-
ing assays, and transwell migration assays, that assessed 
the anti-proliferative and migratory effect on in vitro. The 
effect of the selected small molecule on the sprouting of 
VSMCs from endothelium-denuded aortic rings was also 
examined. The results indicated that the selected small 
molecule, a spleen tyrosine kinase (Syk) inhibitor (BAY61-
3606), is an effective agent for suppressing proliferation 
and migration of VSMCs in  vitro and ex  vivo and that 
has therapeutic potential for treating occlusive vascular 
disease involving aberrant proliferation and migration of 
VSMCs.
Results
Initial screening of small molecules for anti‑proliferative 
effect on VSMCs
For initial screening, through a literature search, 43 small 
molecules (Table  1), whose effects on VSMC prolifera-
tion and migration had not been reported, were selected 
from an in-house small molecule library mainly com-
posed of commercially available inhibitors of six kinase 
subfamilies [10]. The effect of those 43 small molecules 
on VSMC proliferation was then examined. VSMCs 
were treated with each small molecule (10 μM) for 24 h, 
and cellular proliferation was determined by using a cell 
proliferation assay kit (CCK-8). The results indicated 
that the small molecule number 129 most significantly 
inhibited the proliferation of VSMCs, compared to the 
vehicle groups (DMSO 2%, v/v) (Fig. 1). The identity of 
compound 129 was BAY 61-3606 hydrochloride, a Syk 
inhibitor [11].
BAY61 inhibits VSMC proliferation in a concentration 
and time‑dependent manner
To examine the concentration-dependent effect of 
the Syk inhibitor (BAY61), VSMCs were treated with 
increasing concentrations of BAY61 (1, 5, 10, and 20 μM) 
for 24 h. The cellular proliferation results indicated that 
BAY61 had a significant anti-proliferative effect at all 
concentrations tested, although the effect was more pro-
found with concentrations of 5  μM or higher (Fig.  2a, 
b). At the concentration of 10  μM, BAY61 showed a 
significant anti-proliferative effect without any promi-
nent morphological changes. On the other hand, at a 
concentration of 20 μM, the cells started to detach from 
the culture plate and to clump together. Therefore, for 
further experiments, 10  μM was used to examine the 
anti-proliferative effects of BAY61. To further exam-
ine the time-dependent effect of BAY61, VSMCs were 
treated with 10 μM of BAY61 for up to 48 h, and the cel-
lular proliferation was decreased by BAY61 in a time-
dependent manner (Fig. 2c).
Table 1 List of small molecules used for initial screening 
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Anti‑migratory effect of the Syk inhibitor
To evaluate the anti-migratory effect of BAY61, wound 
healing assays and transwell migration assays were con-
ducted. According to the data, when the cells were stim-
ulated with 10% FBS, the scratching wound produced 
with a yellow pipet tip was approximately 90% closed 
at 24  h, but the wound treated with BAY61 (10  μM) 
remained about 50% unclosed (Fig.  3a). Furthermore, 
BAY61 apparently decreased the number of cells that 
migrated through the transwell even in the presence of 
10% serum (Fig. 3b).
BAY61 suppresses VSMC sprouting from aortic rings 
ex vivo
To further investigate the effect of BAY61 on VSMC pro-
liferation, an ex vivo aortic ring assay was performed. The 
endothelium-denuded thoracic aortas of rats were cut to 
prepare aortic rings with thickness of 1  mm. Matrigel-
embedded aortic rings were cultured in 10% FBS-sup-
plemented DMEM with either vehicle (DMSO 2%, v/v) 
or BAY61 (10  μM) for 7  days. VSMC sprouting from 
the endothelium-denuded aortic rings was inhibited by 
BAY61 even in the presence of 10% FBS in the culture 
medium (Fig. 4).
Discussion
In the present study, through a screening of small mol-
ecule inhibitors of kinase subfamilies, we identified a 
Syk inhibitor as a potent anti-proliferative and migratory 
small molecule for VSMCs. Protein kinases are known 
to play critical roles in signaling pathways implicated in 
development, differentiation, death and proliferation of 
cells [12]. Therefore, it is reasonable to hypothesize that 
a certain kinase inhibitor can suppress proliferation and 
migration of VSMCs. Regarding the effect of BAY61 on 
cellular proliferation and migration, it has been reported 
that BAY61 significantly reduced the proliferation and 
migration of multiple myeloma cells [13] and it pre-
vented airway epithelial cell proliferation and migration 
[14]. However, to our best knowledge, no previous study 
had reported anti-proliferative and migratory effects of 
this particular small molecule on VSMCs. Therefore, the 
present study is the first study to examine the effect of 
BAY61 on VSMC proliferation and migration.
Syk, along with zeta-chain associated kinase of 70 kDa 
(Zap-70), is a member of the Syk family of kinases that 
are activated downstream of Src kinases [15]. Syk is 
known to be mainly expressed in hematopoietic cells, but 
its expression has been also reported in epithelial cells 
and endothelial cells [16, 17]. The reported roles of Syk 
include, but not limited to, relaying adaptive immune 
receptor signaling, cellular adhesion, innate immune rec-
ognition, platelet activation, and vascular development 
[18]. Pertaining to the role of Syk in VSMC proliferation, 
it has been reported that inhibition or knockdown of Syk 
significantly prevented platelet-derived growth factor 
(PDGF)-induced proliferation and migration [19].
Our data also clearly demonstrated that the Syk inhib-
itor BAY61 significantly suppressed VSMC proliferation 
and migration. Previous study had reported that sup-
pression of Syk activation led to subsequent inhibition 
of extracellular signal-regulated kinas (ERK) 1/2 sign-
aling and p38 mitogen-activated protein kinase signal-
ing [20]. Therefore, it is highly possible that BAY61 also 
inhibited VSMC proliferation and migration via sup-
pression of ERK and p38 pathways. Although we did 
not examined detailed mechanisms of BAY61 and it 
is a major limitation of the present study, we are cur-
rently conducting a further study evaluating the in vivo 
efficacy of BAY61 in comparison to other well-known 
SMC proliferation inhibitor such as paclitaxel and the 
underlying mechanism of BAY61 will be also examined 
in detail.
Our ex  vivo aortic ring assay result showed that 
BAY61 prevented sprouting of VSMCs, and further-
more, suppression of Syk has been suggested to be 
an effective way to control atherosclerosis via subse-
quent suppression of endothelin-1 production from 
Fig. 1 Initial screening of small molecules for VSMC proliferation 
suppression. A total of 43 small molecule inhibitors of various kinases 
with no reported anti‑proliferative effect on VSMC were screened. Rat 
VSMCs were treated with 10 μM of each small molecule for 24 h, and 
the cellular proliferation was evaluated by cell counting kits (CCK‑8). 
Un (vehicle): 10% FBS supplemented DMSO containing DMSO 2%, 
v/v, indicated as white box with oblique pattern. Blue arrow indi‑
cates the most effective small molecule. The quantitative data were 
expressed as the mean ± SEM of at least three independent experi‑
ments. Full names of each small molecule are listed in Table 1
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Fig. 2 BAY61 inhibits VSMC proliferation in a concentration and time‑dependent manner. a Representative images of VSMCs cultured with increas‑
ing concentrations of BAY61 for 24 h. Scale bar 200 μm. b The concentration‑dependent effect of BAY61 on VSMC proliferation was determined after 
24 h of BAY61 treatment as indicated using cell counting kit (CCK‑8). *p < 0.05, **p < 0.01 compared to 10% FBS control. c To examine the time‑
dependent effect of BAY61, VSMCs were cultured in 10% FBS supplemented DMEM containing either vehicle (DMSO 2%, v/v) or 10 μM of BAY61 
for up to 48 h. Cellular proliferation was determined by using CCK‑8. *p < 0.05, **p < 0.01 compared to 10% FBS control. The quantitative data were 
expressed as the mean ± SEM of at least three independent experiments
endothelial cells [21]. Therefore, BAY61 is a strong 
candidate for an effective therapeutic agent targeting 
occlusive vascular diseases, such as restenosis, and it 
deserves further investigation to prove its in  vivo effi-
cacy and safety.
Conclusions
In summary, as an effort to identify anti-proliferative 
agent to control occlusive vascular disease, this paper 
describes the anti-proliferative and migratory effects of 
BAY61, a Syk inhibitor, on VSMCs for the first time. The 
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selected Syk inhibitor significantly suppressed VSMC 
proliferation and migration in  vitro and ex  vivo. These 
data suggest that the BAY61 may be a potent therapeutic 
agent for the treatment of occlusive vascular disease and 
warrants further studies to evaluate its in  vivo efficacy 
and detailed underlying mechanism.
Methods
Isolation and culture of rat aortic VSMCs
All experimental procedures for animal studies were 
approved by the Committee for the Care and Use of 
Laboratory Animals, Yonsei University College of Medi-
cine, and were performed in accordance with the Com-
mittee’s guidelines and regulations for animal care. Rat 
aortic VSMCs were isolated and cultured using methods 
previously published [22]. The thoracic aortas from 6- 
to 8-week-old Sprague–Dawley rats were removed and 
transferred to serum-free Dulbecco’s modified Eagle’s 
medium (DMEM; Invitrogen, USA) containing 100 units/
ml penicillin and 100  mg/ml streptomycin. The connec-
tive tissues were removed, and the aorta was transferred 
to a petri dish containing 5  ml of an enzyme dissocia-
tion mixture containing DMEM with 1  mg/ml colla-
genase type I (Sigma, USA) and 0.5 mg/ml elastase (USB 
Bioscience, USA) and was incubated for 30 min at 37 °C. 
The adventitia was stripped with forceps under a micro-
scope. The aorta was transferred to a plastic tube contain-
ing 5 ml enzyme dissociation mixture and incubated for 
2 h at 37  °C. The suspension was centrifuged (1500 rpm 
for 10  min), and the pellet was re-suspended with 10% 
fetal bovine serum (FBS) containing DMEM with. Rat 
aortic SMCs were cultured in DMEM supplemented with 
10% FBS, 100 IU/ml penicillin and 100 mg/ml streptomy-
cin in 75 cm2 flasks at 37 °C in a humidified atmosphere of 
95% air and 5% CO2 (Forma Scientific, USA).
Primary screening of small molecules
From an in-house small molecule library mainly com-
posed of inhibitors of six major kinase subfamilies, 43 
candidate small molecules with no known anti-prolifer-
ative effects on VSMCs were selected based on a pub-
lished literature search using Pubmed (http://www.ncbi.
nlm.nih.gov/pubmed). For primary screening, VSMCs 
were seeded in 48-well culture plates using DMEM with 
10% FBS and then treated with 10 μM of each candidate 
compound for 24  h. The anti-proliferative effects of the 
candidate compounds were determined by a cell prolif-
eration assay.
Fig. 3 BAY61 suppresses migration of VSMCs. a Representative images of VSMC wound healing with or without BAY61 treatment. The cells were 
treated with either vehicle (DMSO 2%) or BAY61 (10 μM) after wound was generated by scratching with a yellow pipette tip. The cellular migration 
was monitored for 24 h. Dotted line indicates leading edge. Scale bar 200 μm. *p < 0.05. The quantitative data were expressed as the mean ± SEM of 
at least three independent experiments. b The anti‑migratory effect of BAY61 (10 μM, 24 h) was evaluated by using transwell migration assay. Scale 
bar 200 μm
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Cell proliferation assay (cell counting kit 8, CCK 8)
To determine cell proliferation, cell proliferation assay 
using a WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt] solution (CCK-8, Dojindo, Japan) was 
conducted following protocol previously published [23]. 
Briefly, WST-8 solution was added to each well [10% 
(v/v)] and incubated at 37 °C for 2 h to allow for the for-
mation of WST-8 formazan. The absorbance of a water 
soluble formazan dye was measured at 450  nm using a 
microplate reader (Molecular Devices, USA).
Wound healing assay
Wound healing assay, also as known as in  vitro scratch 
assay, was conducted according to the protocol previ-
ously published [24]. VSMCs were plated at a density 
of 8  ×  104 cells/well in six-well plates. After the cells 
had reached 90% confluence, wounds were produced by 
scratching with 200  μl pipette tips. The leading edge of 
the wounds was marked as a baseline. The medium was 
replaced with or without the chemical compound, and 
the cells were incubated for up to 48 h. Images were cap-
tured using an Axiovert 40C inverted microscope (Carl 
Zeiss, Germany) equipped with a Powershot A640 digi-
tal camera (Canon, Japan). The percent area remained 
unclosed (area between the leading edges at a given time 
point/area between the leading edges at baseline × 100) 
was measured.
Transwell migration assay
Transwell migration assay was performed according to 
the protocol previously published [25]. VSMCs (8 × 103 
cells) were seeded onto the upper chamber of a tran-
swell filter with 8 μm pores (Costar Corning, USA). The 
cells were deprived of serum for 24  h, and a candidate 
chemical compound was added to the lower chamber. 
Transwell chambers were incubated at 37  °C for 24  h. 
After incubation, the cells that migrated through the 
pores of the filter were stained with 0.25% crystal violet. 
Non-migrating cells on the upper side of the filter were 
removed with cotton swabs.
Western Blot analysis
VSMCs cultured in 60-mm dishes were treated with 
or without the selected chemical compound. Proteins 
were separated in a 10% SDS–polyacrylamide gel and 
transferred to PVDF membranes (Millipore, USA). 
After blocking the membrane with TBS-T (TBS-tween 
20, 0.1% tween 20) containing 5% (w/v) non-fat dried 
skimmed milk powder for 1 h at room temperature, the 
membranes were washed twice with TBS-T and incu-
bated with primary antibodies for 1 h at room tempera-
ture or overnight at 4  °C. The membranes were washed 
three times with TBS-T for 5  min and incubated with 
horseradish peroxidase (HRP)-conjugated second-
ary antibody for 1 h at room temperature. After exten-
sive washing, the bands were detected using enhanced 
Fig. 4 BAY61 attenuates VSMC outgrowth from endothelium denuded aortic ring. To examine the effect of BAY61 on the outgrowth of VSMCs from 
blood vessel, segments of endothelium‑denuded aortic rings embedded in Matrigel were treated with either vehicle (DMSO 2%, v/v) or BAY61 
(10 μM) for 7 days. On day 7, the pictures of VSMC sprouting from the aortic ring were taken. White arrows indicate the sprouting of VSMCs from the 
aortic rings. *p < 0.05. The quantitative data were expressed as the mean ± SEM of at least three independent experiments
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chemiluminescence (ECL®) reagent (AbClon, Repub-
lic of Korea). The band intensities were detected using 
a Photo-Image System (Molecular Dynamics, Can-
ada). The primary antibodies were from Cell Signaling 
(cyclin D1:2978, p-ERK:9101, ERK:9102, p-Akt:9271, 
Akt:9272), Santa Cruz [PCNA (proliferating cell nuclear 
antigen):sc-56, p-Rb:sc-16670-R, Rb:sc-50], and Abcam 
(β-actin:ab8227).
Ex vivo aortic ring assay
Aortic ring assay to monitor the outgrowth of VSMCs 
was conducted following a published protocol with 
modifications [26]. Briefly, the thoracic aortas from 6- 
to 8-week-old Sprague–Dawley rats were removed and 
transferred to serum-free DMEM. The lining endothe-
lium was denuded using a 2-Fr Fogarty balloon catheter 
(Baxter, USA) to minimize the possibility of endothe-
lial cell sprouting during the ring assay. The aortas were 
washed by gradually passing through PBS three times. 
After removing perivascular adipose tissue, each aorta 
was cut into segments of aortic rings 1  mm in length 
that were placed in Matrigel (BD Biosciences, USA). The 
aortic rings were incubated with or without the selected 
chemical compound. Over the next 7  days, the aorta 
rings were monitored daily for the sprouting of VSMCs 
using a microscope.
Statistical analysis
Quantitative data were expressed as the mean  ±  SEM 
(standard error of measurement). For statistical analy-
sis, one-way ANOVA with Bonferroni correction was 
performed using OriginPro 8 SR4 software (ver. 8.0951, 
OriginLab Corporation, USA) if there were more than 
three groups. A p value of less than 0.05 was considered 
statistically significant.
Authors’ contributions
HS participated in the study design, carried out cell culture including cell 
preparation, and revised the manuscript. SK drafted the manuscript and 
carried out small molecule screening. CL, KL, and JL participated in cell 
preparation and cell culture. SLim provided technical support. SLee conceived 
the study, drafted the manuscript, and revised the manuscript. KH conceived 
the study and edited the manuscript. All authors read and approved the final 
manuscript.
Author details
1 Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, 
South Korea. 2 Institute for Bio‑Medical Convergence, College of Medicine, 
Catholic Kwandong University, Gangneung‑si, Gangwon‑do, South Korea. 
3 Department of Integrated Omics for Biomedical Sciences, Yonsei University, 
Seoul, South Korea. 4 Department of Veterinary Physiology, College of Vet‑
erinary Medicine, Chonbuk National University, Jeonju, Jeollabuk‑Do, South 
Korea. 
Acknowledgements
This study was supported by grants funded by the Korea Ministry 
of Science, ICT and Future Planning (NRF‑2015M3A9E6029519, and 
NFR‑2015M3A9E6029407).
Competing interests
The authors declare that they have no competing interests.
Received: 19 September 2016   Accepted: 9 December 2016
References
 1. Rensen SS, Doevendans PA, van Eys GJ. Regulation and characteristics 
of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 
2007;15(3):100–8.
 2. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in 
atherosclerosis. Cardiovasc Res. 2012;95(2):156–64.
 3. Louis SF, Zahradka P. Vascular smooth muscle cell motility: from migration 
to invasion. Exp Clin Cardiol. 2010;15(4):e75–85.
 4. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular 
smooth muscle cell differentiation in development and disease. Physiol 
Rev. 2004;84(3):767–801.
 5. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle 
cell differentiation. J Vasc Surg. 2007;45(Suppl A):A25–32.
 6. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruc‑
tion: pharmacologic control of intimal hyperplasia—a review. J Vasc Surg. 
1991;13(6):885–91.
 7. Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numer‑
ous causes of drug‑eluting stent restenosis. Circ Cardiovasc Interv. 
2011;4(2):195–205.
 8. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 
2010;56(10 Suppl):S1–42.
 9. Schomig A, Kastrati A, Wessely R. Prevention of restenosis by systemic 
drug therapy: back to the future? Circulation. 2005;112(18):2759–61.
 10. Hwang KC, Kim JY, Chang W, Kim DS, Lim S, Kang SM, et al. Chemi‑
cals that modulate stem cell differentiation. Proc Natl Acad Sci USA. 
2008;105(21):7467–71.
 11. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Nakashima 
K, et al. The orally available spleen tyrosine kinase inhibitor 
2‑[7‑(3,4‑dimethoxyphenyl)‑imidazo[1,2‑c]pyrimidin‑5‑ylamino]nicoti‑
namide dihydrochloride (BAY 61‑3606) blocks antigen‑induced airway 
inflammation in rodents. J Pharmacol Exp Ther. 2003;306(3):1174–81.
 12. Bononi A, Agnoletto C, De Marchi E, Marchi S, Patergnani S, Bonora M, 
et al. Protein kinases and phosphatases in the control of cell fate. Enzyme 
Res. 2011;2011:329098.
 13. Koerber RM, Held SA, Heine A, Kotthoff P, Daecke SN, Bringmann A, et al. 
Analysis of the anti‑proliferative and the pro‑apoptotic efficacy of Syk 
inhibition in multiple myeloma. Exp Hematol Oncol. 2015;4:21.
 14. Wang X, Mychajlowycz M, Lau C, Gutierrez C, Scott JA, Chow CW. Spleen 
tyrosine kinase mediates BEAS‑2B cell migration and proliferation and 
human rhinovirus‑induced expression of vascular endothelial growth 
factor and interleukin‑8. J Pharmacol Exp Ther. 2012;340(2):277–85.
 15. Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of 
molecular switches. Cell Signal. 2010;22(8):1175–84.
 16. Kurosaki T. Functional dissection of BCR signaling pathways. Curr Opin 
Immunol. 2000;12(3):276–81.
 17. Inatome R, Yanagi S, Takano T, Yamamura H. A critical role for Syk in 
endothelial cell proliferation and migration. Biochem Biophys Res Com‑
mun. 2001;286(1):195–9.
 18. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player 
in diverse biological functions. Nat Rev Immunol. 2010;10(6):387–402.
 19. Gao Z, Cao L, Luo Q, Wang X, Yu L, Wang T, et al. Spleen tyrosine kinase 
modulates the proliferation and phenotypes of vascular smooth 
muscle cells induced by platelet‑derived growth factor. DNA Cell Biol. 
2011;30(3):149–55.
 20. Lee CK, Lee HM, Kim HJ, Park HJ, Won KJ, Roh HY, et al. Syk contributes to 
PDGF‑BB‑mediated migration of rat aortic smooth muscle cells via MAPK 
pathways. Cardiovasc Res. 2007;74(1):159–68.
 21. Kim YJ, Koo TY, Yang WS, Han NJ, Jeong JU, Lee SK, et al. Activation of 
spleen tyrosine kinase is required for TNF‑alpha‑induced endothe‑
lin‑1 upregulation in human aortic endothelial cells. FEBS Lett. 
2012;586(6):818–26.
Page 8 of 8Seo et al. Biol Res  (2017) 50:1 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 22. Kim MH, Ham O, Lee SY, Choi E, Lee CY, Park JH, et al. MicroRNA‑365 inhib‑
its the proliferation of vascular smooth muscle cells by targeting cyclin 
D1. J Cell Biochem. 2014;115(10):1752–61.
 23. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y, Ueno K. A highly water‑
soluble disulfonated tetrazolium salt as a chromogenic indicator for 
NADH as well as cell viability. Talanta. 1997;44(7):1299–305.
 24. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and 
inexpensive method for analysis of cell migration in vitro. Nat Protoc. 
2007;2(2):329–33.
 25. Marshall J. Transwell((R)) invasion assays. Methods Mol Biol. 
2011;769:97–110.
 26. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D’Amico G, et al. 
Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc. 
2011;7(1):89–104.
